Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2023-11-21 00:00:00 ET · period of report 2023-11-20 · accession 0000875320-23-000043 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-21 | 2023-11-20 | VRTX | WAGNER CHARLES F JR | EVP, CFO | S - Sale | $349.88 | -3,000 | 46.7K | -6% | -$1.05M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-20 | S | D | 3,000 | $349.88 | 46,693 | D | — | — | (F3) Open market sales reported on this line occurred at a weighted average price of $349.88 (range $349.76 to $350.00). (F2) Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |